Phase II studies of dianhydrogalactitol-based combination chemotherapy for recurrent brain tumors.
The drug combinations of dianhydrogalactitol and VP-16 and dianhydrogalactitol, VP-16, and triazinate were used in patients with primary brain tumors, principally astrocytoma, recurrent following cranial irradiation. Tumor regressions were noted in 40% of patients treated with the 2-drug regimen and in 33% of patients treated with the 3-drug regimens. Regression were noted in all grades of tumor. Poor performance score on the patients' part did not seem to effect regression rates. Myelosuppression was the principal toxicity encountered. Dianhydrogalactitol-based combination chemotherapy seems as active as nitrosourea therapy and presents an alternative to nitrosourea therapy.
D000293:Adolescent; D000328:Adult; D001254:Astrocytoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D003961:Dianhydrogalactitol / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011034:Podophyllotoxin / Q000627:therapeutic use*; D013402:Sugar Alcohols / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D014227:Triazines / Q000627:therapeutic use*
D013402:Sugar Alcohols; D014227:Triazines; D003961:Dianhydrogalactitol; C012071:triazinate; D011034:Podophyllotoxin